- Home
- EDRY vs CALC Comparison
EDRY vs CALC Comparison
Compare EDRY & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- CALC
- Stock Information
- Founded
- EDRY 2018
- CALC 2011
- Country
- EDRY Greece
- CALC United States
- Employees
- EDRY N/A
- CALC N/A
- Industry
- EDRY Marine Transportation
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- CALC Health Care
- Exchange
- EDRY Nasdaq
- CALC Nasdaq
- Market Cap
- EDRY 24.6M
- CALC 26.7M
- IPO Year
- EDRY N/A
- CALC N/A
- Fundamental
- Price
- EDRY $8.13
- CALC $1.71
- Analyst Decision
- EDRY
- CALC Strong Buy
- Analyst Count
- EDRY 0
- CALC 3
- Target Price
- EDRY N/A
- CALC $16.33
- AVG Volume (30 Days)
- EDRY 3.4K
- CALC 33.7K
- Earning Date
- EDRY 06-10-2025
- CALC 05-14-2025
- Dividend Yield
- EDRY N/A
- CALC N/A
- EPS Growth
- EDRY N/A
- CALC N/A
- EPS
- EDRY N/A
- CALC N/A
- Revenue
- EDRY $61,083,227.00
- CALC N/A
- Revenue This Year
- EDRY N/A
- CALC N/A
- Revenue Next Year
- EDRY $42.57
- CALC N/A
- P/E Ratio
- EDRY N/A
- CALC N/A
- Revenue Growth
- EDRY 28.35
- CALC N/A
- 52 Week Low
- EDRY $7.60
- CALC $1.43
- 52 Week High
- EDRY $24.84
- CALC $5.99
- Technical
- Relative Strength Index (RSI)
- EDRY 36.95
- CALC 42.74
- Support Level
- EDRY $7.60
- CALC $1.66
- Resistance Level
- EDRY $8.86
- CALC $1.83
- Average True Range (ATR)
- EDRY 0.45
- CALC 0.11
- MACD
- EDRY -0.09
- CALC -0.02
- Stochastic Oscillator
- EDRY 22.60
- CALC 15.31
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.